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1. Introduction
Since the advent of prosthetic joint replacement surgery, patients with arthritis have had
significant improvement in pain-relief, mobility and quality of life. Approximately 90,000
Australians undergo joint replacement surgery each year [1]. With an ageing population,
this  number  will  increase  (figure  1).  Similar  data  from  USA  predicts  that  by  2030  the
number of procedures per year will  increase to 4.05 million [2].  Despite the overall  suc‐
cess of this surgery, infection of the prosthesis remains a devastating complication [3]. Of
concern, the incidence of prosthetic joint infection is increasing, in proportion to the num‐
ber  of  procedures  being  performed [4].  Significant  patient  morbidity  is  associated  with
prosthetic joint infections, including the need for further operative procedures, long-term
antibiotic therapy with associated toxicity, and prolonged hospitalisation [3]. In addition,
the cost to the health system is substantial. The cost of treating infection is 3-5 times the
cost of primary arthroplasty [5, 6]. In Australia, the annual additional expenditure incur‐
red as a result of this devastating complication is estimated at AUD $90 million per year
[6]. In the United States, the annual cost of treatment of prosthetic joint infection is pro‐
jected to exceed US$1.6 billion dollars by 2020[7].
The incidence of prosthetic joint infection is estimated at 1-3% of all prosthetic joint replace‐
ments [3]. In prosthetic hip replacement, the rate of infection is estimated at 0.88% and in
knee replacement at 0.92%[4]. The incidence of prosthetic joint infections is higher for upper
limb arthroplasty; in shoulders the incidence of infection is 1.8-4% and in elbow replace‐
ments the incidence of infection is 3-7.5% of patients [8-10].
© 2013 Peel et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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Figure 1. Prosthetic Joint Replacement Surgery in Australia (adapted from AOA National Joint Replacement Registry[1])
A number of pre-operative factors have been implicated in the development of prosthetic
joint infection, including revision arthroplasty, diabetes mellitus and rheumatoid arthritis
[11-16]. The risk factors for prosthetic joint infection differ according to the joint replaced.
Obesity plays a greater role in the evolution of prosthetic joint infection in lower limb ar‐
throplasty [17-19]. The presence of post-operative wound complications, including high
drain tube losses, wound discharge and superficial surgical site infection have been impli‐
cated as risk factors for development of prosthetic joint infection in hip and knee arthroplas‐
ty[11, 20]. In addition the presence of a drain tube appears to be protective for prosthetic
knee infections [17, 18]. Underlying inflammatory arthritis and concomitant steroid use in‐
creases the risk of infections in all arthroplasty surgery but the association is particularly
marked in the upper limb [16, 17]. In addition male gender has been identified as a risk fac‐
tor in shoulder arthroplasty infection, potentially through the interaction with Propionibacte‐
rium acnes (see below)[12].
2. Pathogenesis
There are two main mechanisms of acquisition of prosthetic joint infection; (i) direct inoc‐
ulation of the prosthesis at the time of surgery or with manipulation of the joint and (ii)
seeding from the blood stream at a later time[3]. The pathogenesis of prosthetic joint in‐
fections differs to that of many other bacterial infections through the property of microor‐
ganisms  to  form  biofilms[3].  Microorganisms  can  exist  in  two  phenotypic  forms:  the
planktonic form which is encountered in the majority of acute bacterial infections such as
bacterial septicaemia or pneumonia, and the sessile form associated with medical device
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infections  such as  prosthetic  joint  infections[21].  In  medical  device  associated infections,
the  planktonic  bacteria  seed the  device  and undergo a  phenotypic  change transforming
into the sessile bacteria. The biofilm is comprised of the sessile bacteria and the extracel‐
lular  matrix  they  secrete[21].  This  matrix  protects  the  microorganisms  from  antibiotics
and  the  host  immune  response  and  is  thought  to  be  the  underlying  reason  for  persis‐
tence of infections[21].
3. Microbiology
Staphylococcus  aureus  and  coagulase  negative  Staphylococcus  species  are  the  most  com‐
mon aetiological  agents  of  prosthetic  joint  infections.  The incidence of  methicillin resist‐
ant  strains such as methicillin resistant  Staphylococcus aureus  (MRSA) differ  globally;  the
rate of MRSA prosthetic joint infections across Europe and the Americans MRSA ranges
from 8% to 30%[22-24]. In Australia, 26% of prosthetic joint infections are due to MRSA.
In  addition,  methicillin  resistant  coagulase  negative  Staphylococci  account  for  a  further
22% of isolates [25, 26].
Gram negative bacilli such as Escherichia coli and Pseudomonas aeruginosa are the next most
common isolates[3, 26]. Other microorganisms such as enterococci, streptococci, corynebac‐
terium, fungal species and mycobacterial species are reported less commonly [3, 27]. Of
note, the microbiology of prosthetic joint infection differs between upper limb and lower
limb arthroplasty: Propionibacterium acnes is one of the most common microorganisms en‐
countered in shoulder prosthetic joint infection, occurring in up to 40% of shoulder arthro‐
plasty infections [16, 28, 29]. This association may be due to the increased occurrence of
Propionibacterium acnes around the head and neck, in particular in the sebaceous glands and
hair bulbs [12].
From a review of 6,282 prosthetic hip and knee replacements performed at St Vincent’s Hos‐
pital Melbourne (SVHM) between 2000 and 2012, there were 138 definite infections (table 1).
Prosthetic joint infection was defined by the typical diagnostic criteria which include those
discussed further in table 2. Microorganisms were defined as the causative pathogen/s if iso‐
lated on two or more intra-operative specimens.
The microbiology of hip and knee prosthetic joint infection was similar, except for an in‐
creased number of culture negative infections in prosthetic knee joints and increased isola‐
tion of Enterococcus faecalis from prosthetic hip infections. From SVHM data there was an
increased rate of incisional surgical site infections in knee arthroplasties that later developed
prosthetic joint infections compared to hip arthroplasty (28% versus 12%)[17, 30]. Therefore
it is postulated that the increased number of culture negative infections in the knee replace‐
ment patients may reflect increased antibiotic exposure for superficial wound complications
or for unrecognised prosthetic joint infection.
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Number (%) of
Prosthetic Knee
Infections
(n=66)
Number (%) of
Prosthetic Hip
Infections
(n=72)
Number (%) of All
Prosthetic Joint
Infections
(n=138)
Gram positive organisms 48 (73%) 60 (83%) 108 (78%)
Staphylococcus aureus 25 (38%) 35 (49%) 60 (43%)
Methicillin sensitive 16 (24%) 17 (24%) 33 (24%)
Methicillin resistant 9 (14%) 18 (25%) 27 (20%)
CNS 14 (21%) 13 (18%) 26 (19%)
Methicillin sensitive 1 (2%) 0 1 (1%)
Methicillin resistant 13 (20%) 13 (18%) 26 (19%)
Streptococcus species 4 (6%) 2 (3%) 6 (4%)
Enterococcus faecalis 4 (6%) 10 (14%) 14 (10%)
Other gram positive organisms* 3 (5%) 1 (1%) 4 (3%)
Gram negative organisms 9 (14%) 14 (19%) 23 (17%)
Escherichia coli 1 (2%) 3 (4%) 4 (3%)
Morganella morganii 4 (6%) 0 4 (3%)
Klebsiella pneumoniae 0 1 (1%) 1 (1%)
Serratia marcescens 2 (3%) 0 2 (1%)
Pseudomonas aeruginosa 0 1 (1%) 1 (1%)
Citrobacter koseri 0 1 (1%) 1 (1%)
Enterobacter cloacae 0 3 (4%) 3 (2%)
Proteus mirabilis 2 (3%) 4 (6%) 6 (4%)
Bacteroides fragilis 0 1 (1%) 1 (1%)
Culture negative 17 (26%) 11 (15%) 28 (20%)
CNS = Coagulase negative Staphylococcus species
* Other gram positive isolates included 1 Peptostreptococcus species, 1 Bacillus cereus and 2 Corynebacterium species
Table 1. Microbiology of 138 prosthetic hip and knee joint infections seen at SVHM between 2000 and 2012
4. Clinical classification and presentation
Prosthetic joint infections are classified as (i) early (developing in the first three months after
implantation), (ii) delayed (occurring 3 to 24 months after surgery) and (iii) late (greater than
24 months) or (iv) haematagenous [3]. Haematogenous seeding of the prosthesis typically
occur late (after 24 months) but can occur at any time point following implantation [3, 31].
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The clinical manifestation differs according to time of presentation. In early prosthetic joint
infection, patients typically present with surgical wound complications such as purulent dis‐
charge, erythema and swelling of the affected joint (Figure 2) [3, 32]. In delayed and late in‐
fections, pain is the predominant feature with patients reporting a history of slowly
increasing pain involving the prosthetic joint [32]. Haematogenous infections in contrast,
typically are associated with a history of a joint that was free of any problems for several
months to years before an acute onset of fever, erythema around the surgical wound and
pain in the affected joint[33].
 
A 
B 
Figure 2. Early Prosthetic Hip Joint Infection (A) at presentation with infection showing wound erythema, swelling
and purulent discharge and (B) intra-operative appearance showing purulence surrounding the prosthetic joint.
The presentation of shoulder arthroplasty infection due to Propionibacterium acnes is general‐
ly delayed or late[12]. The classic features of infection are frequently absent with pain and
stiffness of the joint the predominant symptoms [12, 34]. Bruising along the surgical wound
has been described as a pathognomonic sign of Propionibacterium acnes shoulder arthroplasty
infection [34].
5. Diagnosis of prosthetic joint infections
The diagnosis of infections is challenging due to the absence of an internationally accepted
gold standard for defining arthroplasty infection. Current definitions rely on a number of pa‐
rameters including clinical, microbiological and histopathological features (Table 2) [3, 35-39].
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Prompt recognition and diagnosis of prosthetic joint infection is imperative to minimize pa‐
tient suffering and to improve patient outcomes [40]. Isolation of the causative microorganism
is the most important diagnostic test as it allows confirmation of diagnosis and assessment of
antimicrobial susceptibilities. Infection of the prosthesis is suggested by the isolation of the
same microorganism from 2 or more intra-operative specimens [3, 35, 36] To increase the likeli‐
hood of diagnosis, ≥5 peri-prosthetic tissue specimens should be obtained intra-operatively
with each specimen placed in separate sterile containers [35, 36]. This is of particular impor‐
tance for skin commensals such as Propionibacterium acnes and coagulase negative Staphylococ‐
cus species to aid in distinguishing true infection from specimen contamination.
The diagnosis of prosthetic joint infection should be considered in patients with any of the following [3, 36-39]:
Presence of peri-prosthetic purulence observed intra-operatively; OR
Isolation of indistinguishable micro-organism/s on ≥2 intra-operative specimens (tissue or joint aspirate cultures); OR
Presence of a sinus tract in communication with the prosthetic joint; OR
Histopathological features of acute infections with ≥5 neutrophils per-high power field (x 500 magnifications) in 5
different microscopic fields.
Table 2. Diagnosis of Prosthetic Joint Infection
Prior exposure to antibiotic therapy increases the risk of culture negative prosthetic joint in‐
fection [30, 37, 41]. Therefore antibiotic therapy should not be commenced until after obtain‐
ing multiple intra-operative specimens, except in the case of the septic patient in whom
commencement of antibiotic therapy should not be delayed. In patients with delayed and
late infections, who have received antibiotic therapy prior to obtainment of intra-operative
cultures, definitive surgery may be delayed for 2-4 weeks after cessation of antibiotics to in‐
crease the intra-operative yield[30, 37, 41].
Sonication of the explanted prosthesis disrupts the biofilm and may increase the diagnostic
yield of microbiological culture. Sonication is particularly useful in patients who have re‐
ceived antibiotics in 14 days preceding surgery [37]. Prolongation of microbiological cul‐
tures from 3 to 14 days also increases the diagnostic yield, particularly of more fastidious
organisms such as Propionibacterium acnes [42].
6. Management of prosthetic joint infection
The goal of treatment of prosthetic joint infection is to eradicate the biofilm dwelling micro‐
organisms, whilst maintaining function of the joint and patient quality of life[3].
The surgical strategies to manage prosthetic joint infection include: (i) one-stage or two-
stage exchange procedures, (ii) debridement and retention of the prosthesis in conjunction
with biofilm active antibiotics, (iii) removal of the prosthesis +/- arthrodesis, (iv) amputation
of the affected limb and (v) chronic suppression without surgical debridement of the infect‐
ed joint. Removal of the prosthesis and amputation are associated with significant impair‐
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ment of mobility. Chronic suppression is association with a high rate of recurrence of
infection. Therefore these strategies are reserved for patients with significant co-morbidities
or in patients with recalcitrant infection [3, 33]. Exchange procedures and debridement and
retention are the two strategies that best meet the goals of treatment [3, 33].
Figure 3. SVHM Protocol Algorithm for Management of Prosthetic Joint Infection
Given the heterogeneous nature of prosthetic joint infections there are no large randomized
control trials to guide recommendations. Surgical strategies differ significantly worldwide; ex‐
Management of Prosthetic Infection According to Organism
http://dx.doi.org/10.5772/53244
523
change procedures are the favoured treatment modality in Northern America, whereas de‐
bridement and retention is more commonly performed in Australia and parts of Europe [3, 26,
33]. A number of treatment algorithms exist to guide management decisions and these are
based on factors such as duration of symptoms, the stability of implant, patient co-morbidities
and the type of infecting microorganism[3, 33]. Compared to the exchange procedures, pa‐
tients managed with debridement and retention of the implant undergo fewer and less exten‐
sive surgical procedures and have shorter duration of hospitalisation and immobilisation [3,
33, 43]. Therefore early and haematogenous infections can be managed by debridement and re‐
tention. However, if the implant is loose, if the duration of symptoms prior to presentation ex‐
ceed 21 days or if the isolated pathogen is resistant to biofilm-active antibiotics, the likelihood
of treatment success for debridement and retention is markedly reduced[3, 33]. Therefore if the
patient has any of the above features, expert opinion recommends patients undergo prosthesis
exchange (either as a one-stage or two-stage procedure). Delayed or late prosthetic joint infec‐
tions should be managed by one- or two-stage exchange; debridement and retention of the
prosthesis in this setting is associated with a high failure rate[3, 33].
At SVHM, a management protocol was established through collaboration between the Ortho‐
paedic and Infectious Diseases Departments. The abbreviated algorithm is shown in Figure 3.
The antibiotic regimens for different pathogens are detailed in Table 3. At SVHM patients man‐
aged by debridement and retention of the prosthesis undergo 3 debridements of the infected
joint. The liner is changed, where feasible, but other mobile parts are not routinely changed.
This differs from other protocols for debridement and retention, in which patients undergo a
single debridement with exchange of all mobile parts and liners [33]. Regardless of technique,
the aim of the debridement/s is to reduce the microbial burden prior to instigation of antibiotic
therapy with activity against the biofilm-dwelling microorganisms.
7. Staphylococcus aureus and coagulase negative Staphylococcus species
Rifampicin  has  excellent  activity  against  Staphylococcal  biofilms and is  the  mainstay  of
treatment  in  these infections,  particularly  with debridement  and retention [3,  33,  44-46].
Older  treatment  algorithms recommended against  debridement  and retention for  MRSA
however, emerging evidence suggests that this is a suitable strategy in carefully selected
patients [33, 46, 47].
Staphylococcus  becomes  rapidly  resistant  to  rifampicin  if  this  antibiotic  is  used  alone,
therefore rifampicin must always be administered with a second agent (companion drug)
[48].  Fluoroquinolones,  such  as  ciprofloxacin,  are  frequently  used  as  companion  drugs
however fluoroquinolone resistance is increasing thus limiting the utility of this combina‐
tion[25]. Alternate companion drugs for rifampicin include fusidic acid, trimethoprim-sul‐
famethoxazole,  minocycline,  daptomycin  and  linezolid  [33,  47-52].  There  are  no  clinical
studies comparing the efficacy of different drugs used in combination with rifampicin. In
Australia including SVHM, fusidic acid is commonly prescribed as a companion drug for
rifampicin [47] [26].
Rifampicin based regimens are recommended even for methicillin sensitive isolates. Giv‐
en the high oral bioavailability of rifampicin, a move to oral therapy is suggested as soon
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as  the  patient  can reliably  take oral  diet  after  completion of  surgical  debridements.  For
those  few patients  who are  bacteraemic,  however,  more  prolonged intravenous  therapy
may be required along with appropriate investigation to exclude other foci  of  infection,
such as endocarditis.
In patients with MRSA infections managed with two-stage exchange; the insertion of a
spacer should be avoided as there is an increased rate of treatment failure [3, 33, 53]. In addi‐
tion, an association between the presence of a spacer and the development of rifampicin re‐
sistance in MRSA strains has been reported [53].
8. Streptococcus
Streptococcus are the causative agent in 8% of prosthetic joint infections[26]. In general the
treatment outcomes are excellent for all surgical strategies for Streptococcal arthroplasty in‐
fection [54-58]. However, the outcomes with group B streptococcal infections are mixed with
some studies reporting poorer outcomes with these isolates [58-60]. In general intravenous
benzylpenicillin or ceftriaxone can be used (often for 2 weeks) before a shift to high dose or‐
al amoxicillin. In some circumstances, with typable streptococci where susceptibility to ri‐
fampicin is expected, rifampicin can be added to the amoxicillin as part of the oral regimen
although the evidence for this practice is still not clear.
9. Enterococcus
Enterococcus is an uncommon cause of prosthetic joint infection however, the incidence of
these infections is increasing[61]. At our institution, Enterococcus faecalis was isolated in 10%
of all infections. It is a common isolate in polymicrobial infections of the prosthetic hip joint.
There are little published data to guide treatment of enterococcal prosthetic joint infection.
Some experts recommend treatment strategies extrapolated from other enterococcal infec‐
tions, in particular enterococcal endocarditis [61]. Beta-lactam antibiotics, such as penicillin
are bacteriostatic against enterococci, therefore combination therapy with aminoglycosides
such as gentamicin, is recommended for management of enterococcal endocarditis[62].
However data from retrospective studies suggest there is no additional benefit with combi‐
nation therapy with aminoglycosides in enterococcal prosthetic joint infections and, of great
concern, there was significant nephrotoxicity and ototoxicity associated with aminoglyco‐
side therapy[61]. Euba et al examined the role of ampicillin-ceftriaxone combination thera‐
py, however, only 3 patients with enterococcal prosthetic joint infection were included in
this study and 2 of those patients had late infections[63]. Therefore the role of this combina‐
tion therapy remains unclear and further studies are required. Recent in-vitro models have
suggested rifampicin in combination either with ciprofloxacin or linezolid are the most effi‐
cacious antibiotic combinations against biofilm dwelling Enterococcus faecalis, although
there are no reports at present of the use of these combinations in patients[64].
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Enterococcus faecium is infrequently involved in prosthetic joint infections; however, it
presents significant treatment challenges, owing to increased resistance when compared to
Enterococcus faecalis. In particular, Enterococcus faecium is increasingly resistant to benzylpe‐
nicillin and amoxicillin[62]. There is little clinical data outlining management approaches for
Enterococcus faecium, however, exchange procedures are likely to be the optimal strategy in
these infections. Other resistant enterococcal prosthetic joint infection including vancomycin
resistant enterococcus (VRE), also are very uncommon. In a statewide review of 163 pros‐
thetic joint infections, VRE was isolated once (0.6%). Two-stage exchange of the prosthesis is
recommended for VRE arthroplasty infections in conjunction with agents such as daptomy‐
cin, linezolid or pristinamycin. In all enterococcal infections, including VRE, the use of
spacers in two-stage exchange procedures is not recommended due to the increased risk of
treatment failure [3, 33].
10. Gram negative bacilli
For gram-negative bacilli infections, ciprofloxacin has been shown to be effective in guinea
pig tissue cage models[65]. There is conflicting data on the clinical outcomes of gram-nega‐
tive bacilli infections, particularly with debridement and retention. The reported success rate
for debridement and retention ranges from 27%-94% with a similar range reported for ex‐
change procedures [66-70]. The likelihood of success may relate to the quality of the de‐
bridement and meticulous care should be taken to ensure removal of all dead and
devitalised tissue and removal of all cement in the exchange procedures [69]. In addition,
gram-negative bacteria, particularly Pseudomonas aeruginosa, have a propensity to develop
resistance to fluoroquinolones in-vivo[62]. In light of this, many experts recommend a 2-4
week course of beta-lactam antibiotic prior to commencement of ciprofloxacin to reduce the
bacterial load and thus reduce the likelihood of generation of in-vivo resistance [33].
11. Propionibacterium
As with all other infections, the duration of symptoms dictates the most appropriate surgical
strategy for Propionibacterium acnes prosthetic joint infection. In Propionibacterium arthroplas‐
ty infection, the majority of cases are delayed or late presentations, with a long duration of
symptoms[12]. Therefore prosthesis exchange is the surgical modality of choice.
Evidence of the ability of Propionibacterium acnes to form biofilms is emerging. A number of
in-vitro models have been developed to assess the activity of antibiotics against biofilm-as‐
sociated Propionibacterium. As with staphylococcal biofilm models, the activity of rifampicin
is preserved with Propionibacterium biofilms[71]. The emergence of rifampicin resistance
with monotherapy has not been demonstrated[71]. In one study combination therapy with
daptomycin and rifampicin was the most effective treatment regimen[71]. Other studies
have demonstrated penicillin alone or combination therapy with rifampicin and linezolid
are also effective against Propionibacterium biofilms[72].
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The antibiotic regimens reported to treat patients with Propionibacterium acnes prosthetic
joint infection are diverse and include: penicillin, amoxicillin, ceftriaxone, clindamycin and
rifampicin-fluoroquinolone or rifampicin-clindamycin combination therapy [73, 74]. In gen‐
eral, we recommend IV benzylpenicillin followed by high dose oral amoxicillin combined
with rifampicin.
12. Fungi
Fungal prosthetic joint infections are rare. The majority of fungal prosthetic joint infections
are due to Candida species however, other fungal species have been reported including As‐
pergillus species, Cryptococcus neoformans, Zygomycetes, Histoplasma capsulatum, Rhodotorula
minuta [75-78] (figure 4).
The results for debridement and retention and exchange procedures for management of fun‐
gal prosthetic joint are poor. In treatment guidelines from the Infectious Diseases Society of
America, resection arthroplasty is recommended for prosthetic joint infection due to candi‐
dal species[79]. In addition, the use of a spacer following resection of the prosthesis is associ‐
ated with a high rate of failure and should be avoided [75, 80]. If reimplantation is
considered following prosthesis resection, a prolonged period (3-6 months) prior to reinser‐
tion is recommended [81]. Finally, in candidal prosthetic joint infections, there is emerging
evidence that the activity of caspofungin is better preserved in the presence of biofilm, com‐
pared to fluconazole [80, 82]. For other non candidal fungi, individualized expert advice
should be sought to guide antimicrobial choice.
 
 
 
These microbiological cultures were 
obtained from a patient with disseminated 
Rhizopus infection including prosthetic hip 
joint involvement. The patient had significant 
comorbidities and was managed with 
debridement and retention of the prosthesis 
and long-term posaconazole therapy[76].  
 
Figure 4. Rhizopus species cultured from an infected prosthetic hip joint. Photo courtesy of Dr Harsha Sheorey, Micro‐
biology Department, St Vincent’s Hospital Melbourne.
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13. Culture negative
One of the greatest challenges in management is the ‘culture negative’ prosthetic joint in‐
fection. In published case series,  the reported rate of culture-negative prosthetic joint in‐
fection  ranges  from  5-41%  [3,  27,  83].  A  number  of  factors  contribute  to  the  failure  of
microbiological cultures to isolate a pathogen including poor culture technique (including
obtaining fewer than 5 intra-operative specimens),  fastidious organisms that are difficult
to culture and prior antibiotic  exposure that  impedes bacterial  growth.  Of these mecha‐
nisms, prior antibiotic exposure is the most common reason for failing to isolate a causa‐
tive  pathogen.  In  some  studies,  44%  of  patients  with  culture  negative  prosthetic  joint
infection  were  receiving  antibiotic  therapy at  the  time of  obtainment  of  microbiological
specimens[30]. Indeed, the receipt of antibiotics in the 3 months prior to presentation with
prosthetic joint infection, lead to a 5-fold increased chance of culture-negative prosthetic
joint infection [41].
The choice of antibiotic treatment in culture negative prosthetic joint infection should be
guided by local ecology. In addition, if patients had prior exposure to antibiotic therapy, the
spectrum of these antibiotics may also influence subsequent antibiotic selection. The results
for culture negative prosthetic joint infection are generally similar to culture positive pros‐
thetic joint infection [41].
14. Conclusion
With an ageing population and the increasing popularity of arthroplasty, prosthetic joint in‐
fection will continue to present a diagnostic and management challenge to clinicians. Treat‐
ment approaches for arthroplasty infection are still under debate, in particular, optimal
treatment strategy for different microorganisms. Increasing understanding of the role of bio‐
film in the pathogenesis of prosthetic joint infections and investigation of the activity of dif‐
ferent antimicrobial agents against biofilm associated microorganisms will provide
important information to guide therapy. In addition, multicentre studies and collaborative
research groups are key to providing more detailed treatment particularly for less common‐
ly encountered pathogens.
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